FGFR2 and pancreatic ductal adenocarcinoma: The proposed methodology was validated using two well-established kinases, FGFR2 and IGF1R, whose roles have been linked in various pathological conditions (e.g., pancreatic ductal adenocarcinoma, PDAC).